대한의생명과학회지 (Biomedical Science Letters)

  • 제28권2호
  • /
  • Pages.67-82
  • /
  • 2022
  • /
  • 1738-3226(pISSN)
  • /
  • 2288-7415(eISSN)
대한의생명과학회 (The Korean Society for Biomedical Laboratory Sciences)
권호 표지
DOI QR코드

DOI QR Code

Comparison of COVID-19 Vaccines Introduced in Korea

  • Lee, Chang-Gun (Department of Medical Genetics, Ajou University School of Medicine) ;
  • Lee, Dongsup (Department of Clinical Laboratory Science, Hyejeon College)
  • 투고 : 2022.05.23
  • 심사 : 2022.06.10
  • 발행 : 2022.06.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The prevalence of SARS-CoV-2 led to inconsistent public health policies that resulted in COVID-19 containment failure. These factors resulted in increased hospitalization and death. To prevent viral spread and achieve herd immunity, the only safe and effective measure is to provide to vaccinates. Ever since the release of the SARS-CoV-2 nucleotide sequence in January of 2020, research centers and pharmaceutical companies from many countries have developed different types of vaccines including mRNA, recombinant protein, and viral vector vaccines. Prior to initiating vaccinations, phase 3 clinical trials are necessary. However, no vaccine has yet to complete a phase 3 clinical trial. Many products obtained "emergency use authorization" from governmental agencies such as WHO, FDA etc. The Korean government authorized the use of five different vaccines. The viral vector vaccine of Oxford/AstraZeneca and the Janssen showed effectiveness of 76% and 66.9%, respectively. The mRNA vaccine of Pfizer-BioNTech and Moderna showed effectiveness of 95% and 94.1%, respectively. The protein recombinant vaccine of Novavax showed an effectiveness of 90.4%. In this review, we compared the characteristics, production platform, synthesis principles, authorization, protective effects, immune responses, clinical trials and adverse effects of five different vaccines currently used in Korea. Through this review, we conceptualize the importance of selecting the optimal vaccine to prevent the COVID-19 pandemic.

키워드

과제정보

This research was supported by Hyejeon College grant.

참고문헌

  1. Anderson M, Stec M, Rewane A, et al. SARS-CoV-2 antibody responses in infection-naive or previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. JAMA Netw Open. 2021. 4: e2119741. https://doi.org/10.1001/jamanetworkopen.2021.19741
  2. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther. 2000. 7: 1034-1038. https://doi.org/10.1038/sj/gt/3301197
  3. Businesswire.com. Moderna announces primary efficacy analysis in phase 3 COVE study for Its COVID-19 vaccine candidate and filing today with U.S. FDA for emergency use authorization. https://www.businesswire.com/news/home/20201130005506/en/Moderna-Announces-Primary-Efficacy-Analysis-in-Phase-3-COVE-Study-for-Its-COVID-19-Vaccine-Candidate-and-Filing-Today-with-U.S.-FDA-for-Emergency-Use-Authorization as of 2020. 11. 30.
  4. Centers for Disease Control and Prevention (CDC). Johnson & Johnson's Janssen COVID-19 Vaccine Information. https://www.cdc.gov/vaccines/covid-19/info-by-product/janssen/index.html as of 2021a. 3. 29.
  5. Centers for Disease Control and Prevention (CDC). Pfizer-BioNTech COVID-19 vaccine (also known as Comirnaty) overview and safety. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html as of 2022. 5. 20. -48
  6. Centers for Disease Control and Prevention (CDC). Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine-United States, December2020. 14-23. https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm?s_cid=mm7002e1_w as of 2021b. 1. 6.
  7. Centers for Disease Control and Prevention (CDC). The possibility of COVID-19 after vaccination: Breakthrough infections. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness/why-measure-effectiveness/breakthrough-cases.html#anchor_1636141727968 as of 2021c. 12. 17.
  8. Choi DO, Lee KM. Development of COVID-19 neutralizing anti-body (NAb) detection kits using the S1 RBD protein of SARSCoV-2. Korean J Clin Lab Sci. 2021. 53: 257-265. https://doi.org/10.15324/kjcls.2021.53.3.257
  9. Chung YH, Beiss V, Fiering SN, Steinmetz NF. COVID-19 vaccine frontrunners and their nanotechnology design. ACS Nano. 2020. 14: 12522-12537. https://doi.org/10.1021/acsnano.0c07197
  10. Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021. 384: 2254-2256. https://doi.org/10.1056/NEJMe2106315
  11. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021. 384: 1412-1423. https://doi.org/10.1056/NEJMoa2101765
  12. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021. 371: eabf4063. https://doi.org/10.1126/science.abf4063
  13. Department of Health and Social Care. One year anniversary of UK deploying Oxford-AstraZeneca vaccine. https://www.gov.uk/government/news/one-year-anniversary-of-uk-deploying-oxford-astrazeneca-vaccine as of 2022. 1. 4.
  14. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. N Engl J Med. 2021. 384: 2259-2261. https://doi.org/10.1056/NEJMc2103916
  15. Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022. 386: 531-543. https://doi.org/10.1056/NEJMoa2116185
  16. European Medicines Agency (EMA). Vaxzevria: EMA advises against use in people with history of capillary leak syndrome. https://www.ema.europa.eu/en/news/vaxzevria-ema-advises-against-use-people-history-capillary-leak-syndrome as of 2021a. 6. 11.
  17. European Medicines Agency (EMA). Comirnaty. https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty as of 2022a. 3. 12.
  18. European Medicines Agency (EMA). Spikevax (previously COVID19 Vaccine Moderna). https://www.ema.europa.eu/en/medicines /human/EPAR/spikevax as of 2022b. 5. 12
  19. European Medicines Agency (EMA). Nuvaxovid. https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid as of 2021b. 12. 23.
  20. Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020. 396: 467-478. https://doi.org/10.1016/S0140-6736(20)31604-4
  21. Frederiksen LSF, Zhang Y, Foged C, Thakur A. The long road toward COVID-19 herd immunity: Vaccine platform technologies and mass immunization strategies. Front Immunol. 2020. 11: 1817. https://doi.org/10.3389/fimmu.2020.01817
  22. Gaebler C, Nussenzweig MC. All eyes on a hurdle race for a SARS-CoV-2 vaccine. Nature. 2020. 586: 501-502. https://doi.org/10.1038/d41586-020-02926-w
  23. Goel RR, Apostolidis SA, Painter MM, et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. Sci Immunol. 2021. 6: eabi6950. https://doi.org/10.1126/sciimmunol.abi6950
  24. Greenwood B. The contribution of vaccination to global health: Past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014. 369: 20130433. https://doi.org/10.1098/rstb.2013.0433
  25. Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021. 384: 2092-2101. https://doi.org/10.1056/NEJMoa2104840
  26. Guo L, Wang G, Wang Y, et al. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: A longitudinal cohort study. Lancet Microbe. 2022. 3: e348-e356. https://doi.org/10.1016/S2666-5247(22)00036-2
  27. Heath PT, Galiza EP, Baxter DN, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. N Engl J Med. 2021. 385: 1172-1183. https://doi.org/10.1056/NEJMoa2107659
  28. Hotez PJ, Bottazzi ME. Whole Inactivated Virus and Protein-Based COVID-19 Vaccines. Annu Rev Med. 2022. 73: 55-64. https://doi.org/10.1146/annurev-med-042420-113212
  29. Howard J. FDA grants full approval to Pfizer/BioNTech Covid-19 vaccine, opening door to more vaccine mandates. https://edition.cnn.com/2021/08/23/health/fda-approval-pfizer-covid-vaccine/index.html as of 2021. 8. 23.
  30. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated immunity to coronaviruses: Antibody kinetics, correlates of protection, and association of antibody responses with severity of disease. medRxiv. 2020. 20065771.
  31. Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2-Preliminary report. N Engl J Med. 2020. 383: 1920-1931. https://doi.org/10.1056/NEJMoa2022483
  32. James G, Nick T. Covid-19: Oxford-AstraZeneca coronavirus vaccine approved for use in UK. https://www.bbc.com/news/health-55280671 as of 2020. 12. 30.
  33. Jenco J. Moderna testing COVID-19 vaccine in children under 12. https://publications.aap.org/aapnews/news/12031 as of 2021.
  34. Kandeil A, Mostafa A, Hegazy RR, et al. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine: Preclinical studies. Vaccines (Basel). 2021. 9: 214. https://doi.org/10.3390/vaccines9030214
  35. Keech C, Albert G, Cho I, et al. Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine. N Engl J Med. 2020. 383: 2320-2332. https://doi.org/10.1056/NEJMoa2026920
  36. Kesselheim AS, Darrow JJ, Kulldorff M, et al. An overview of vaccine development, approval, and regulation, with implications for COVID-19. Health Aff. 2021. 40: 25-32. https://doi.org/10.1377/hlthaff.2020.01620
  37. Kim MW. A review of recent trend of COVID-19 infection and correlation with pulmonary function. Biomed Sci Lett. 2020a. 26: 127-135. https://doi.org/10.15616/BSL.2020.26.3.127
  38. Kim EJ, Lee DS. Coronaviruses: SARS, MERS and COVID-19. Korean J Clin Lab Sci. 2020b. 52: 297-309. https://doi.org/10.15324/kjcls.2020.52.4.297
  39. Korea Disease Control and Prevention Agency, Cases of COVID-19 in Korea 2022a. http://ncov.mohw.go.kr/bdBoardList_Real.do
  40. Korea Disease Control and Prevention Agency. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6569&contSeq=6569&board_id=312&gubun=ALL as of 2022b. 4. 14.
  41. Korea Disease Control and Prevention Agency. http://ncov.mohw.go.kr/tcmBoardView.do?brdId=3&brdGubun=31&dataGubun=&ncvContSeq=6531&board_id=312&contSeq=6531 as of 2022c. 3. 31.
  42. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020. 584: 457-462. https://doi.org/10.1038/s41586-020-2550-z
  43. Leo L. Hope to launch Covovax by September, says Serum Institute CEO. https://www.livemint.com/companies/news/hope-to-launch-covovax-by-september-says-serum-institute-ceo-11616834205232.html as of 2021. 5. 27.
  44. MacNeil JR, Su JR, Broder KR, et al. Updated recommendations from the advisory committee on immunization practices for use of the Janssen (Johnson & Johnson) COVID-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients-United States, April 2021. https://www.cdc.gov/mmwr/volumes/70/wr/mm7017e4.htm as of 2021. 4. 30.
  45. Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines. Eur Rev Med Pharmacol Sci. 2021. 25: 1663-1669.
  46. Ministry of Food and Drug Safety of Korea. Press release in Ministry of Food and Drug Safety of Korea. file:///C:/Users/ajoumg/Downloads/1.12+%EB%B0%94%EC%9D%B4%EC%98%A4%EC%9D%98%EC%95%BD%ED%92%88%EC%A0%95%EC%B1%85%EA%B3%BC+%EB%93%B1.pdf as of 2022. 1. 12.
  47. Mulligan MJ, Lyke KE, Kitchin N, et al. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020. 586: 589-593. https://doi.org/10.1038/s41586-020-2639-4
  48. National Health Service (NHS). Coronavirus vaccine. https://www.nhs.uk/conditions/coronavirus-covid-19/coronavirus-vaccination/coronavirus-vaccine/ as of 2022. 5. 12.
  49. Novavax. Novavax publishes results of United Kingdom phase 3 clinical trial in New England Journal of Medicine, demonstrating high levels of efficacy of COVID-19 vaccine. https://ir.novavax.com/2021-06-30-Novavax-Publishes-Results-of-United-Kingdom-Phase-3-Clinical-Trial-in-New-England-Journal-of-Medicine,-Demonstrating-High-Levels-of-Efficacy-of-COVID-19-Vaccine?sf146717139=1 as of 2021. 6. 30.
  50. Nunneley CE. COVID-19 vaccine candidates: 6 front-runners. https://abcnews.go.com/Health/covid-19-vaccine-candidates-front-runners/story?id=69881230 as of 2020. 4. 1.
  51. Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. Jama. 2022. 327: 331-340. https://doi.org/10.1001/jama.2021.24110
  52. Pfizer. Pfizer and BioNTech conclude phase 3 study of COVID-19 vaccine candidate, meeting all primary efficacy endpoints. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-conclude-phase-3-study-covid-19-vaccineas of 2020. 11. 18.
  53. Piano Mortari E, Russo C, Vinci MR, et al. Highly specific memory B cells generation after the 2nd dose of BNT162b2 vaccine compensate for the decline of serum antibodies and absence of mucosal IgA. Cells. 2021. 10: 2541. https://doi.org/10.3390/cells10102541
  54. Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2021. 396: 1979-1993.
  55. Salzman S. Johnson & Johnson single-shot vaccine 85% effective against severe COVID-19 disease. https://web.archive.org/web/20210201092739/https://abcnews.go.com/Health/johnson-johnson-single-shot-vaccine-85-effective-severe/story?id=75557358 as of 2021. 1. 29.
  56. Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020. 11: 585354. https://doi.org/10.3389/fimmu.2020.585354
  57. Shay DK, Gee J, Su JR, et al. Safety monitoring of the Janssen (Johnson & Johnson) COVID-19 vaccine - United States, March-April 2021. MMWR Morb Mortal Wkly Rep. 2021. 70: 680-684. https://doi.org/10.15585/mmwr.mm7018e2
  58. Shinde V, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. N Engl J Med. 2021. 384: 1899-1909. https://doi.org/10.1056/NEJMoa2103055
  59. Song GS, Lee YR, Kim SM, et al. Laboratory diagnosis of coronavirus disease 19 (COVID-19) in Korea: Current status, limitation, and challenges. Korean J Clin Lab Sci. 2020. 52: 284-295. https://doi.org/10.15324/kjcls.2020.52.3.284
  60. Team CC-R, U.S. Food and Drug Administration. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020- January 10, 2021. MMWR Morb Mortal Wkly Rep. 2021. 70: 125-129. https://doi.org/10.15585/mmwr.mm7004e1
  61. Teijaro JR, Farber DL. COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol. 2021. 21: 195-197. https://doi.org/10.1038/s41577-021-00526-x
  62. The Guardian. Spain, Belgium and Italy restrict AstraZeneca Covid vaccine to older people. https://www.theguardian.com/society/2021/apr/08/spain-belgium-and-italy-restrict-astrazeneca-covid-vaccine-to-older-people as of 2021a. 4. 8.
  63. The Guardian. Fully vaccinated people account for 1.2% of England's Covid-19 deaths. https://www.theguardian.com/world/2021/sep/13/fully-vaccinated-people-account-for-12-of-englands-covid-19-deaths as of 2021b. 9. 13.
  64. Tregoning JS, Brown ES, Cheeseman HM, et al. Vaccines for COVID-19. Clin Exp Immunol. 2020. 202: 162-192. https://doi.org/10.1111/cei.13517
  65. Turonova B, Sikora M, Schurmann C, et al. In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges. Science. 2020. 370: 203-208. https://doi.org/10.1126/science.abd5223
  66. U.S. Food and Drug Administration. FDA Briefing document Janssen Ad26.COV2.S vaccine for the prevention of COVID-19. https://www.fda.gov/media/146217/download as of 2021a. 2. 26.
  67. U.S. Food and Drug Administration. FDA issues emergency use authorization for third COVID-19 vaccine. https://web.archive.org/web/20210318174827/https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine as of 2021b. 2. 27.
  68. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals. https://www.fda.gov/news-events/pressannouncements/coronavirus-covid-19-update-fda-limits-use-janssen-covid-19-vaccine-certain-individuals as of 2022. 5. 5.
  69. van Doremalen N, Lambe T, Spencer A, et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature. 2020. 586: 578-582. https://doi.org/10.1038/s41586-020-2608-y
  70. Vogel G, Frankel JC. Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. https://www.science.org/content/article/israel-reports-link-between-rare-cases-heart-inflammation-and-covid-19-vaccination as of 2021. 6. 1.
  71. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021a. 397: 99-111. https://doi.org/10.1016/S0140-6736(20)32661-1
  72. Voysey M, Costa Clemens SA, Madhi SA, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: A pooled analysis of four randomised trials. Lancet. 2021b. 397: 881-891. https://doi.org/10.1016/S0140-6736(21)00432-3
  73. Wadman M. Novavax launches pivotal U.S. trial of dark horse COVID-19 vaccine after manufacturing delays. https://www.science.org/content/article/novavax-launches-pivotal-us-trial-dark-horse-covid-19-vaccine-after-manufacturing as of 2020a. 12. 28.
  74. Wadman M. The long shot. Science. 2020b. 370: 649-653. https://doi.org/10.1126/science.370.6517.649
  75. Walls AC, Park YJ, Tortorici MA et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020. 181: 281-292; e6. https://doi.org/10.1016/j.cell.2020.02.058
  76. Walsh EE, Frenck RW Jr., Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020. 383: 2439-2450. https://doi.org/10.1056/NEJMoa2027906
  77. Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021. 384: 80-82. https://doi.org/10.1056/NEJMc2032195
  78. World Health Organization (WHO). Weekly epidemiological update on COVID-19-20 April 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---20-april-2022 as of 2022. 4. 20.
  79. World Health Organization (WHO). Background document to the WHO interim recommendations for use of the mRNA-1273 vaccine (Moderna), 3 February 2021. http://apps.who.int/iris/handle/10665/339218 as of 2021. 2. 3.
  80. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020a. 579: 265-269. -8 https://doi.org/10.1038/s41586-020-2008-3
  81. Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020b. 27: 325-328. -11 https://doi.org/10.1016/j.chom.2020.02.001
  82. Zhang C, Maruggi G, Shan H, Li J. Advances in mRNA vaccines for infectious diseases. Front Immunol. 2019. 10: 594. https://doi.org/10.3389/fimmu.2019.00594
  83. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020. 579: 270-273 https://doi.org/10.1038/s41586-020-2012-7